CY2100B1 - Compounds for treating inflammatory bowel disease - Google Patents

Compounds for treating inflammatory bowel disease

Info

Publication number
CY2100B1
CY2100B1 CY9800024A CY9800024A CY2100B1 CY 2100 B1 CY2100 B1 CY 2100B1 CY 9800024 A CY9800024 A CY 9800024A CY 9800024 A CY9800024 A CY 9800024A CY 2100 B1 CY2100 B1 CY 2100B1
Authority
CY
Cyprus
Prior art keywords
inflammatory bowel
bowel disease
treating inflammatory
compounds
benzyl
Prior art date
Application number
CY9800024A
Other languages
English (en)
Inventor
Jaswant Singh Gidda
Jull Ann Panetta
Michael Leroy Phillips
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CY2100B1 publication Critical patent/CY2100B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Eye Examination Apparatus (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Surgical Instruments (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CY9800024A 1989-12-21 1998-09-07 Compounds for treating inflammatory bowel disease CY2100B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45420389A 1989-12-21 1989-12-21

Publications (1)

Publication Number Publication Date
CY2100B1 true CY2100B1 (en) 2002-04-05

Family

ID=23803709

Family Applications (1)

Application Number Title Priority Date Filing Date
CY9800024A CY2100B1 (en) 1989-12-21 1998-09-07 Compounds for treating inflammatory bowel disease

Country Status (22)

Country Link
EP (1) EP0434394B1 (ja)
JP (1) JP3036853B2 (ja)
KR (1) KR0176243B1 (ja)
CN (1) CN1029846C (ja)
AT (1) ATE169294T1 (ja)
AU (1) AU639734B2 (ja)
CA (1) CA2032330C (ja)
CY (1) CY2100B1 (ja)
DE (1) DE69032537T2 (ja)
DK (1) DK0434394T3 (ja)
ES (1) ES2121748T3 (ja)
FI (2) FI104251B1 (ja)
HU (1) HU216732B (ja)
IE (1) IE904633A1 (ja)
IL (3) IL108962A (ja)
MX (1) MX23803A (ja)
NO (1) NO300458B1 (ja)
NZ (1) NZ236472A (ja)
PT (1) PT96198B (ja)
RU (2) RU2036915C1 (ja)
YU (1) YU240690A (ja)
ZA (1) ZA9010041B (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU87339A1 (fr) * 1988-09-20 1990-04-06 Oreal Nouveaux derives de benzylidene-cyclanones,leur procede de preparation,leur utilisation en tant qu'agents anti-oxydants et comme filtres solaires,compositions cosmetiques et pharmaceutiques les contenant
US5143928A (en) * 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
ZA936492B (en) * 1992-09-10 1995-03-02 Lilly Co Eli Compounds useful as hypoglycemic agents and for treating Alzheimer's disease.
DK0595546T3 (da) * 1992-10-28 1996-04-15 Shionogi & Co Benzylidenderivater
US6251928B1 (en) 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
US5563277A (en) * 1994-12-21 1996-10-08 Eli Lilly And Company Process for preparing benzyl-substituted rhodanine derivatives
EP0761657B1 (en) * 1995-09-07 2000-05-24 Eli Lilly And Company Process for preparing benzyl-substituted rhodanine derivatives
IN182320B (ja) * 1995-09-07 1999-03-20 Lilly Co Eli
EP0779282A1 (en) * 1995-12-14 1997-06-18 Eli Lilly And Company Thiomorpholinone compounds for treating multiple sclerosis
US5981523A (en) * 1996-02-05 1999-11-09 Eli Lilly And Company Compounds and methods for treating multiple sclerosis
US6063799A (en) * 1996-09-03 2000-05-16 Eli Lilly And Company Alternate crystal form of Tazofelone
US6005142A (en) 1996-09-03 1999-12-21 Eli Lilly And Company Process for preparing benzyl-substituted rhodanine derivatives
WO2000018746A1 (en) * 1998-09-30 2000-04-06 Roche Diagnostics Gmbh Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders
EP1117655A1 (en) 1998-09-30 2001-07-25 Angelika Esswein Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders
AU6330999A (en) * 1998-09-30 2000-04-17 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
US7235573B2 (en) 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
NZ538809A (en) * 2002-09-30 2008-06-30 Univ California Thiazolidinone cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
AU2002953533A0 (en) 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
JP5778755B2 (ja) * 2010-04-15 2015-09-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ヒドロキノンの製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1285572C (en) * 1985-08-09 1991-07-02 Jill Ann Panetta Di-t-butylphenol compounds
IE62214B1 (en) * 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
DE69027472T2 (de) * 1989-04-07 1996-12-05 Lilly Co Eli Arylsubstituierte Rhodaninderivate

Also Published As

Publication number Publication date
FI104251B (fi) 1999-12-15
JP3036853B2 (ja) 2000-04-24
AU639734B2 (en) 1993-08-05
DK0434394T3 (da) 1998-12-14
ES2121748T3 (es) 1998-12-16
NZ236472A (en) 1993-03-26
JPH04279573A (ja) 1992-10-05
IL108962A0 (en) 1994-06-24
RU2050355C1 (ru) 1995-12-20
CA2032330C (en) 2001-05-08
CN1029846C (zh) 1995-09-27
PT96198B (pt) 1998-05-29
ATE169294T1 (de) 1998-08-15
PT96198A (pt) 1991-09-30
EP0434394B1 (en) 1998-08-05
IL96654A (en) 1995-06-29
YU240690A (sh) 1992-12-21
NO300458B1 (no) 1997-06-02
FI906273A0 (fi) 1990-12-19
CA2032330A1 (en) 1991-06-22
DE69032537D1 (de) 1998-09-10
HU908368D0 (en) 1991-07-29
FI906273A (fi) 1991-06-22
MX23803A (es) 1994-02-28
ZA9010041B (en) 1992-08-26
RU2036915C1 (ru) 1995-06-09
NO905478L (no) 1991-06-24
IE904633A1 (en) 1991-07-17
AU6826690A (en) 1991-06-27
IL108962A (en) 1996-12-05
NO905478D0 (no) 1990-12-19
EP0434394A3 (en) 1992-01-08
CN1052668A (zh) 1991-07-03
EP0434394A2 (en) 1991-06-26
DE69032537T2 (de) 1999-01-21
FI19991698A (fi) 1999-08-10
KR0176243B1 (ko) 1999-03-20
HUT59915A (en) 1992-07-28
HU216732B (hu) 1999-08-30
FI104251B1 (fi) 1999-12-15
KR910011812A (ko) 1991-08-07

Similar Documents

Publication Publication Date Title
ZA9010041B (en) Compounds for treating inflammatory bowel disease
DE68913860D1 (de) Pressform und Formgebungsverfahren zum Herstellen von optischen Teilen.
HUT56356A (en) Process for producing thiazolidin-4-ones and 1,3-oxathiolan-5-one derivatives
GB2241509B (en) Process for the sintered-metal production of moulded parts from intermetallic compounds
PT97547A (pt) Processo para a preparacao de novas pirido {2,3-f}{1,4}tiazepinas e pirido {3,2-b}{1,5}benzotiazepinas e de composicoes farmaceuticas que as contem
DZ1335A1 (fr) Procédé stéréospecifique pour la préparation des énantiomères de la furo (3,4-c) pyridine et composéainsi obtenus.
EP0443406A3 (en) Process for enzymatic racemate separation of pantolacton
EP0799215A4 (en) PROCESS FOR THE PREPARATION OF BENZYL-SUBSTITUTED RHODANINE DERIVATIVES
HUT56344A (en) Process for producing 2,4,5-tribromopyrrol-3-carbonitrile derivatives
CS53688A2 (en) Method of new substituted 3-phenyl-7h-thiazolo/3,2-b//1,2,4/triazine -7-ons production
HU908032D0 (en) Process for producing new sulfatic derivatives of galactane extracted from klebsiella
HU63191D0 (en) Hexahydrobenz(c,d)indole derivatives and process for producing them
HU9203625D0 (en) Stereoselective process for producing optical isomers of 1-benzoyl-4-hydroxi-5-(1-phenyl-ethyl)-amino-1,2,2a,3,4,5-hexahydrobenz/cd/-indole
HUT60324A (en) Process for producing compositions of yeast biomass base
TW396865U (en) The punching molds for the toothlike parts by method of sectional rapid machining process
HU203068B (en) Process for producing 2-(3,4-disubsituted phenyl)-3-mehtylbutyric acids, their optical isomers, as well as alpha-cyano-m-phenoxybenzyl esters